Close Menu

BioArray Briefs: 2009.02.17

Premium

SQI Diagnostics CE Marks Diagnostics Platform

SQI Diagnostics last week said that it is now authorized to use the CE Mark with its SQiDworks Diagnostics Platform. The Toronto-based company also said it is authorized to use the CE Mark for its array-based QuantiSpot Rheumatoid Arthritis Assay. SQI said it will now be able to market its QuantiSpot RA test to diagnostic laboratories in the European Union.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Lancet and the New England Journal of Medicine have issued expressions of concern regarding the data used in two COVID-19 papers, the New York Times reports. 

An Associated Press report says China refrained from releasing the SARS-CoV-2 genome for more than a week in January, frustrating the World Health Organization.

Researchers have sequenced the genome of the mayfly, garnering insight into how insects evolved wings, Science reports.

In Genome Research this week: gene expression in primate brain regions, inversions and breakpoint inverted repeats in the human genome, and more.